Literature DB >> 300622

T-lymphocytes and survival of head and neck squamous cell carcinoma.

J M Mason, G G Kitchens, R J Eastham, B R Jennings.   

Abstract

The thymus-dependent lymphocytes (T cells) were enumerated in the peripheral circulation of 38 patients with histologically demonstrated squamous cell carcinoma of the head and neck. We have previously shown that this "total" T-cell count correlates well with degree of tumor involvement. A lower percentage of T cells were shown in patients with more advanced malignant neoplasms. Here we present follow-up data on these patients to evaluate the efficiency of the T-cell test in determining survival prognoses. We found no evidence that results of this test can extend prognostic abilities above those based on clinical staging. The survival data from six patients treated with a chemoimmunotherapy regimen of BCG vaccine, methotrexate sodium, and isoniazid did not demonstrate an increased survival time compared to patients at similar clinical stages who were treated by conventional use of surgery and irradiation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300622     DOI: 10.1001/archotol.1977.00780210079009

Source DB:  PubMed          Journal:  Arch Otolaryngol        ISSN: 0003-9977


  3 in total

1.  Stimulation of peripheral blood lymphocytes with autologous tumor and serum-derived fractions from patients with laryngeal carcinomas.

Authors:  P Koldovsky; U Koldovsky; J Ebbers; K H Vosteen
Journal:  Arch Otorhinolaryngol       Date:  1986

2.  Nutritional and immunological investigations in head and neck cancer patients before and after therapy.

Authors:  H Picker; E Bichler
Journal:  Arch Otorhinolaryngol       Date:  1985

3.  Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma.

Authors:  Ana Caruntu; Liliana Moraru; Mihaela Surcel; Adriana Munteanu; Daniel Octavian Costache; Cristiana Tanase; Carolina Constantin; Cristian Scheau; Monica Neagu; Constantin Caruntu
Journal:  Healthcare (Basel)       Date:  2022-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.